Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies.

Soldatos CR, Dikeos DG, Whitehead A.

Int Clin Psychopharmacol. 1999 Sep;14(5):287-303.

PMID:
10529072
2.

Rebound insomnia and rebound anxiety: a review.

Kales A, Soldatos CR, Bixler EO, Kales JD.

Pharmacology. 1983;26(3):121-37. Review.

PMID:
6132413
3.

Rebound insomnia: a critical review.

Gillin JC, Spinweber CL, Johnson LC.

J Clin Psychopharmacol. 1989 Jun;9(3):161-72. Review.

PMID:
2567741
4.

Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects.

Kales A, Kales JD.

J Clin Psychopharmacol. 1983 Apr;3(2):140-50. Review.

PMID:
6132933
5.

Quazepam: hypnotic efficacy and side effects.

Kales A.

Pharmacotherapy. 1990;10(1):1-10; discussion 10-2. Review.

PMID:
1969151
6.

Rebound insomnia and elimination half-life: assessment of individual subject response.

Bixler EO, Kales JD, Kales A, Jacoby JA, Soldatos CR.

J Clin Pharmacol. 1985 Mar;25(2):115-24. Review.

PMID:
2859304
8.

Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Noble S, Langtry HD, Lamb HM.

Drugs. 1998 Feb;55(2):277-302. Review.

PMID:
9506247
9.

Insomnia: drug treatment.

Tsoi WF.

Ann Acad Med Singapore. 1991 Mar;20(2):269-72. Review.

PMID:
1679317
10.

Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Hesse LM, von Moltke LL, Greenblatt DJ.

CNS Drugs. 2003;17(7):513-32. Review.

PMID:
12751920
11.

Benzodiazepine hypnotics and insomnia.

Kales A.

Hosp Pract (Off Ed). 1990 Sep;25 Suppl 3:7-21; discussion 22-3. Review.

PMID:
1976124
12.

Comparative clinical profiles of triazolam versus other shorter-acting hypnotics.

Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW.

J Clin Psychiatry. 1992 Dec;53 Suppl:19-31; discussion 32-3. Review.

PMID:
1336776
13.

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.

Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. Review.

14.

Rebound insomnia and newer hypnotics.

Lader M.

Psychopharmacology (Berl). 1992;108(3):248-55. Review.

PMID:
1523276
15.
16.

Safety of zaleplon in the treatment of insomnia.

Israel AG, Kramer JA.

Ann Pharmacother. 2002 May;36(5):852-9. Review.

PMID:
11978165
17.

Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.

Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A.

Drugs Aging. 2005;22(9):749-65. Review.

PMID:
16156679
18.

[Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine DGSM].

Clarenbach P, Steinberg R, Weess HG, Berger M.

Nervenarzt. 1995 Oct;66(10):723-9. Review. German.

PMID:
7501087
19.

Zaleplon: a review of its use in the treatment of insomnia.

Dooley M, Plosker GL.

Drugs. 2000 Aug;60(2):413-45. Review.

PMID:
10983740
20.

Criteria for selection of appropriate benzodiazepine hypnotic therapy.

Mendels J.

J Clin Psychiatry. 1991 Sep;52 Suppl:42-6. Review.

PMID:
1680126
Items per page

Supplemental Content

Write to the Help Desk